ℹ️
🇨🇿
Hledání
Hledat publikace relevantní k dotazu "Prior lines"
Prior lines
Publikace
Předměty
Osoby
Publikace
Studium
publication
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
2021 |
Lékařská fakulta v Hradci Králové
publication
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
2020 |
1. lékařská fakulta
publication
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
2018 |
Lékařská fakulta v Hradci Králové
publication
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
2023 |
1. lékařská fakulta, Lékařská fakulta v Hradci Králové
publication
Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data
2020 |
1. lékařská fakulta, Lékařská fakulta v Hradci Králové
publication
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia
2015 |
Publikace bez příslušnosti k fakultě
publication
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
2020 |
1. lékařská fakulta
publication
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
2017 |
1. lékařská fakulta
publication
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
2018 |
1. lékařská fakulta
publication
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
2023 |
1. lékařská fakulta
publication
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
2021 |
Publikace bez příslušnosti k fakultě
publication
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
2021 |
1. lékařská fakulta
publication
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
2020 |
Ústřední knihovna
publication
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
2023 |
1. lékařská fakulta
publication
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
2024 |
2. lékařská fakulta